Abstract: The disclosure relates to compositions comprising 3,6,7-trimethyllumazine. In particular, Manuka honey is an example of a composition comprising 3,6,7-trimethyllumazine. The composition is useful in preventing, ameliorating or treating TG2, JAK, and/or COX-2 associated conditions. These conditions include inflammation, pain, ulcers, Crohn's disease, reflux, gingivitis, schizophrenia, neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, arthritis, cardiovascular diseases and cancers.

Abstract: The invention relates to compositions comprising 3,6,7-trimethyllumazine, methods and uses thereof in preventing, ameliorating or treating inflammation and/or preventing, ameliorating or treating conditions associated with inflammation. More particularly, though not solely, the invention relates to compositions comprising 3,6,7-trimethyllumazine and methods of use thereof in preventing, ameliorating or treating MMP-9 associated conditions, such as inflammation of the gastrointestinal tract and/or inflammatory conditions associated with the gastrointestinal tract.

Abstract: The present invention provides compounds that may be useful for provoking an immune response against an epitope in a subject in need thereof

Abstract: The present invention provides a peptide that selectively binds ?v?6 integrin, the peptide having an amino acid sequence comprising the motif X1BnRGDLX2X3X4ZmX5, wherein X1 is any D-amino acid, Bn is a sequence of any n amino acids, which may be natural or unnatural, D- or L-, and may be the same or different, wherein n is a number between 1 and 10, X2 and X3 are independently selected from any amino acid, X4 is Leu or Ile, Zm is a sequence of any m amino acids, which may be natural or unnatural, D- or L-, and may be the same or different, wherein m is a number between 1 and 10, X5 is any L- or D-amino acid. Also provided are conjugates comprising said peptide, pharmaceutical compositions comprising said peptide or said conjugates, and uses of said peptide, conjugate or composition, for example, in the treatment, imaging and/or diagnosis of an ?v?6-expressing tumour in a mammalian subject.

Abstract: A metal nanoparticle-phosphopeptide complex comprising a metal nanoparticle and a phosphopeptide is provided. The phosphopeptide comprises two or more contiguous peptide motifs and two or more phosphorus-containing groups capable of interacting with the surface of the metal nanoparticle. The amino acids at the equivalent position in each peptide motif have similar structural and/or electronic properties. Each phosphorus-containing group is bound to an amino acid in the two or more contiguous peptide motifs. Methods for preparing the metal nanoparticle-phosphopeptide complex are also provided.

Abstract: This invention provides analogs and peptidomimetics of glycyl-L-prolyl-L-glutamic acid (GPE). In particular, this invention relates to GPE analogs and peptidomimetics that are anti-apoptotic, anti-necrotic and have neuroprotective effects. These agents are useful in treating neurodegeneration and behavioural disorders caused by toxins, traumatic brain injury and autoimmune disorders of the brain, such as multiple sclerosis and in reducing seizures.

Abstract: Embodiments of this invention provide novel cyclic compounds structurally related to diketopiperazines and methods for their therapeutic use. Such compounds are neuroprotective and have utility as therapeutic agents for treatment of diseases, injuries and other conditions characterised by neuronal degeneration and/or death. Compounds are also useful for manufacture of medicaments useful for treatment of such conditions.

Abstract: This invention provides compounds, compositions and methods for treating loss of cognitive function in animals that results from aging. In particular, compounds of this invention can stimulate neural cell growth, increased amounts of cells containing a key enzyme needed for production of the cholinergic neurotransmitter, and can improve memory and cognitive function in animals who have experienced a loss of memory or cognitive function as a result of aging.

Abstract: Embodiments of this invention provide methods for thereapeutic use of cyclic G-2-Allyl Proline to treat disorders of dopaminergic neurons, including Parkinson's disease. Cyclic G-2Allyl P is neuroprotective and has utility as a therapeutic agent for treatment of diseases and other conditions characterised by degeneration and/or death of dopaminergic neurons and the adverse symptoms of such degeneration and/or death. Such symptoms include loss of cognition and motor function. Compounds are also useful for manufacture of medicaments including tablets, capsules and injectable solutions that are useful for treatment of such conditions.

Abstract: Aspects of this invention include the use of G-2MePE to treat patients with brain injury characterized by non-convulsive seizures. G-2MePE is useful in treating brain injuries caused by traumatic brain injury, stroke, hypoxia/ischemia and toxic injury.

Abstract: Embodiments of this invention provide novel peptidomimetics that contain a macrocycle. Such compounds are neuroprotective and have utility as therapeutic agents for treatment of diseases, injuries and other conditions characterised by neuronal degeneration and/or death. Compounds are also useful for manufacture of medicaments useful for treatment of such conditions.